EXEL Insider Trading
EXELIXIS, INC. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at EXELIXIS, INC. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2018-03-08 03:23 | 2018-03-06 | MARCHESI VINCENT T | Director | OPT+S | $24.73 | 15,000 | $370,950 | 125,913 | 0.0% |
| 2018-03-08 03:25 | 2018-03-05 | COHEN CHARLES | Director | OPT+S | $24.23 | 15,000 | $363,450 | 248,180 | 0.0% |
| 2018-03-03 04:00 | 2018-02-28 | Haley Patrick J. | Officer - Sr. Vice President, Commercial | OPT+S | $27.13 | 45,029 | $1,221,637 | 113,490 | 0.0% |
| 2018-03-03 04:01 | 2018-03-02 | WILLSEY LANCE | Director | OPT+S | $23.91 | 30,000 | $717,300 | 468,273 | 0.0% |
| 2018-03-03 04:03 | 2018-03-02 | PAPADOPOULOS STELIOS | Director | OPT+S | $24.05 | 15,000 | $360,750 | 1,034,314 | 0.0% |
| 2018-03-03 03:59 | 2018-02-28 | POSTE GEORGE | Director | OPT+S | $26.26 | 15,000 | $393,900 | 83,398 | 0.0% |
| 2018-01-11 03:27 | 2018-01-08 | Garber Alan M | Director | OPT+S | $30.30 | 15,000 | $454,515 | 61,329 | 0.0% |
| 2017-09-29 02:47 | 2017-09-27 | Hessekiel Jeffrey | Officer - EVP and General Counsel | OPT+S | $24.28 | 27,302 | $663,018 | 267,946 | 0.0% |
| 2017-09-29 02:45 | 2017-09-26 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $23.79 | 100,000 | $2,378,670 | 183,005 | 0.0% |
| 2017-09-23 02:07 | 2017-09-22 | PAPADOPOULOS STELIOS | Director | SELL | $25.40 | 10,000 | $254,000 | 0 | -100.0% |
| 2017-09-21 01:48 | 2017-09-18 | PAPADOPOULOS STELIOS | Director | SELL | $27.68 | 200,000 | $5,535,380 | 1,034,314 | -16.2% |
| 2017-09-16 01:43 | 2017-09-14 | Haley Patrick J. | Officer - Sr. Vice President, Commercial | SELL | $27.21 | 60,640 | $1,650,014 | 41,553 | -59.3% |
| 2017-09-15 02:17 | 2017-09-12 | Senner Christopher J. | Officer - EVP and CFO | OPT+S | $26.79 | 100,000 | $2,679,000 | 102,759 | 0.0% |
| 2017-09-15 02:18 | 2017-09-12 | WILLSEY LANCE | Director | SELL | $26.88 | 100,000 | $2,688,000 | 468,273 | -17.6% |
| 2017-09-15 02:14 | 2017-09-12 | MORRISSEY MICHAEL | Director, Officer - President and CEO | OPT+S | $26.90 | 300,000 | $8,070,990 | 60,000 | 0.0% |
| 2017-05-17 04:13 | 2017-05-15 | FELDBAUM CARL B | Director | OPT+S | $21.58 | 32,988 | $711,832 | 34,733 | 0.0% |
| 2017-05-11 03:07 | 2017-05-08 | MORRISSEY MICHAEL | Director, Officer - President and CEO | OPT+S | $21.87 | 211,300 | $4,622,166 | 60,000 | 0.0% |
| 2017-05-06 01:53 | 2017-05-03 | MORRISSEY MICHAEL | Director, Officer - President and CEO | OPT+S | $22.24 | 259,149 | $5,762,826 | 60,000 | 0.0% |
| 2017-05-04 03:02 | 2017-05-01 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $23.01 | 89,910 | $2,068,523 | 170,504 | 0.0% |
| 2017-04-05 03:00 | 2017-04-03 | MARCHESI VINCENT T | Director | OPT+S | $21.30 | 10,000 | $213,000 | 120,070 | 0.0% |
| 2017-04-01 01:35 | 2017-03-31 | WYSZOMIERSKI JACK L | Director | OPT+S | $21.57 | 5,150 | $111,086 | 72,960 | 0.0% |
| 2017-03-29 03:15 | 2017-03-27 | Hessekiel Jeffrey | Officer - EVP and General Counsel | SELL | $21.02 | 6,884 | $144,702 | 267,946 | -2.5% |
| 2017-03-25 02:41 | 2017-03-22 | Hessekiel Jeffrey | Officer - EVP and General Counsel | OPT+S | $20.54 | 23,787 | $488,585 | 277,830 | 0.0% |
| 2017-03-22 02:29 | 2017-03-20 | FELDBAUM CARL B | Director | OPT+S | $21.77 | 10,000 | $217,700 | 48,721 | 0.0% |
| 2017-03-22 02:28 | 2017-03-20 | PAPADOPOULOS STELIOS | Director | OPT+S | $21.66 | 10,000 | $216,600 | 1,228,471 | 0.0% |
| 2017-03-18 02:51 | 2017-03-15 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $22.53 | 50,007 | $1,126,658 | 158,053 | 0.0% |
| 2017-03-18 02:52 | 2017-03-15 | WILLSEY LANCE | Director | OPT+S | $22.86 | 10,000 | $228,600 | 568,273 | 0.0% |
| 2017-03-15 03:12 | 2017-03-13 | COHEN CHARLES | Director | SELL | $21.82 | 10,000 | $218,200 | 238,180 | -4.0% |
| 2017-03-11 03:37 | 2017-03-10 | MARCHESI VINCENT T | Director | OPT+S | $21.98 | 40,000 | $879,200 | 120,070 | 0.0% |
| 2017-03-08 03:45 | 2017-03-03 | Haley Patrick J. | Officer - Sr. Vice President, Commercial | SELL | $23.04 | 2,500 | $57,600 | 107,193 | -2.3% |
| 2017-03-08 04:00 | 2017-03-03 | Hessekiel Jeffrey | Officer - EVP and General Counsel | OPT+S | $23.04 | 100,000 | $2,303,680 | 246,617 | 0.0% |
| 2017-03-08 03:56 | 2017-03-03 | MORRISSEY MICHAEL | Director, Officer - President and CEO | OPT+S | $22.72 | 200,000 | $4,544,000 | 60,000 | 0.0% |
| 2017-03-04 04:20 | 2017-03-03 | Senner Christopher J. | Officer - EVP and CFO | SELL | $22.80 | 11,000 | $250,800 | 100,398 | -9.9% |
| 2017-03-04 04:18 | 2017-03-01 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $22.19 | 45,000 | $998,550 | 73,600 | 0.0% |
| 2017-03-04 04:17 | 2017-03-01 | POSTE GEORGE | Director | OPT+S | $22.53 | 76,250 | $1,718,187 | 77,555 | 0.0% |
| 2017-02-04 03:55 | 2017-02-01 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $18.65 | 70,000 | $1,305,500 | 73,600 | 0.0% |
| 2017-01-06 04:25 | 2017-01-03 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $14.65 | 70,000 | $1,025,633 | 73,600 | 0.0% |
| 2016-12-17 03:29 | 2016-12-16 | FELDBAUM CARL B | Director | OPT+S | $17.03 | 25,000 | $425,750 | 48,721 | 0.0% |
| 2016-12-10 04:02 | 2016-12-09 | Garber Alan M | Director | OPT+S | $16.90 | 7,832 | $132,361 | 61,329 | 0.0% |
| 2016-12-08 03:03 | 2016-12-05 | SCANGOS GEORGE A | Director | OPT+S | $17.81 | 204,894 | $3,649,183 | 1,463,648 | 0.0% |
| 2016-12-03 03:14 | 2016-12-01 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $16.66 | 70,000 | $1,166,200 | 73,600 | 0.0% |
| 2016-12-03 03:13 | 2016-12-01 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $16.73 | 22,000 | $368,060 | 158,053 | 0.0% |
| 2016-11-15 03:34 | 2016-11-09 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $13.15 | 70,000 | $920,500 | 73,600 | 0.0% |
| 2016-11-15 03:36 | 2016-11-09 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $15.00 | 22,000 | $330,000 | 158,053 | 0.0% |
| 2016-11-15 03:37 | 2016-11-09 | MORRISSEY MICHAEL | Director, Officer - President and CEO | OPT+S | $15.00 | 200,000 | $3,000,000 | 60,000 | 0.0% |
| 2016-09-02 23:34 | 2016-08-31 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $10.98 | 131,155 | $1,440,082 | 136,441 | 0.0% |
| 2016-08-06 02:29 | 2016-08-04 | Schwab Gisela | Officer - Pres Prod Dev & Med Aff & CMO | OPT+S | $11.00 | 42,338 | $465,718 | 132,016 | 0.0% |
| 2016-05-12 00:23 | 2016-05-09 | WILLSEY LANCE | Director | BUY | $4.97 | 60,000 | $297,900 | 568,273 | +11.8% |
| 2015-12-12 03:43 | 2015-12-10 | WILLSEY LANCE | Director | BUY | $4.89 | 100,000 | $488,550 | 494,975 | +25.3% |
| 2015-10-20 00:08 | 2015-10-16 | Lamb Peter | Officer - EVP, Discovery Research & CSO | OPT+S | $5.80 | 51,549 | $298,984 | 36,473 | 0.0% |
How to Interpret $EXEL Trades
Not every insider transaction in EXELIXIS, INC. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $EXEL shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for EXEL
Insider activity data for EXELIXIS, INC. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $EXEL, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.